<SEC-DOCUMENT>0001437749-24-029747.txt : 20240920
<SEC-HEADER>0001437749-24-029747.hdr.sgml : 20240920
<ACCEPTANCE-DATETIME>20240920161203
ACCESSION NUMBER:		0001437749-24-029747
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240920
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240920
DATE AS OF CHANGE:		20240920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZEVRA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001434647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				205894398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36913
		FILM NUMBER:		241313504

	BUSINESS ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747
		BUSINESS PHONE:		(321) 939-3416

	MAIL ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM, INC
		DATE OF NAME CHANGE:	20130530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM INC
		DATE OF NAME CHANGE:	20080507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zvra20240920_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:zvra="http://www.zvra.com/20240920"><head>
	<title>zvra20240920_8k.htm</title>

<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 10px; margin-left: 10px; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20248K" name="dei:AmendmentFlag" id="ixv-348">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20248K" name="dei:EntityCentralIndexKey" id="ixv-349">0001434647</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="zvra-20240920.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20248K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001434647</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-09-20</xbrli:startDate>
<xbrli:endDate>2024-09-20</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>
<!-- Generated by ThunderDome Portal - 9/20/2024 4:28:09 PM -->
<hr style="margin: 3pt 0px; border: currentColor; border-image: none; width: 100%; height: 3px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/>
<hr style="margin: 0px 0px 3pt; border: currentColor; border-image: none; width: 100%; height: 1px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/>
<div style="margin: 0pt; text-align: center; color: rgb(0, 0, 0); text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, Serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&#160;</div>

<div style="margin: 0pt; text-align: center; color: rgb(0, 0, 0); text-indent: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 18pt; background-color: rgb(255, 255, 255);"><b>UNITED STATES</b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>WASHINGTON, D.C. 20549 </b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt;"><b>FORM <ix:nonNumeric contextRef="d20248K" name="dei:DocumentType" id="ixv-22"><b>8-K</b></ix:nonNumeric></b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"><span style="font-size:10pt;"><b>CURRENT REPORT </b></span></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="d20248K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-37"><b>September 20, 2024</b></ix:nonNumeric></b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 24pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityRegistrantName" id="ixv-43"><b>Zevra Therapeutics, Inc.</b></ix:nonNumeric></div>

<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Exact Name of Registrant as Specified in Its Charter) </b></div>

<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="TBL1" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-56"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityFileNumber" id="ixv-60"><b>001-36913</b></ix:nonNumeric></div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityTaxIdentificationNumber" id="ixv-64"><b>20-5894398</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
			<td style="width: 33%; vertical-align: top; padding: 0px; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(Commission&#160;File </b></div>
			</td>
			<td style="width: 33%; vertical-align: top; padding: 0px; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(I.R.S. Employer Identification </b></div>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(State or Other Jurisdiction of Incorporation)</b></div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><b>Number)</b></td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><b>No.)</b></td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine1" id="ixv-88"><strong>1180 Celebration Boulevard</strong><strong>, <strong><strong>Suite 103</strong></strong></strong></ix:nonNumeric><strong>,</strong></td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressCityOrTown" id="ixv-98"><strong><strong><strong><strong>Celebration</strong></strong></strong></strong></ix:nonNumeric><strong>, <ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressStateOrProvince" id="ixv-104"><strong><strong><strong><strong><strong><strong>FL</strong></strong></strong></strong></strong></strong></ix:nonNumeric></strong></td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressPostalZipCode" id="ixv-113"><b>34747</b></ix:nonNumeric></td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;"><b>(Address of Principal Executive Offices)&#160;</b></td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 10pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt; text-align: center;"><b>(Zip Code)</b></td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 33.3%; vertical-align: bottom; text-align: center; font-size: 8pt;">&#160;</td>
			<td style="width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Registrant&#8217;s Telephone Number, Including Area Code:&#160;(<ix:nonNumeric contextRef="d20248K" name="dei:CityAreaCode" id="ixv-130"><b>321</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20248K" name="dei:LocalPhoneNumber" id="ixv-132"><b>939-3416</b></ix:nonNumeric></b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(Former Name or Former Address, if Changed Since Last Report)</b></div>

<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB2" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-359">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB3" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-360">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB4" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-361">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB5" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 24pt; vertical-align: top;">
			<div style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-362">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top;">
			<div style="text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt; margin: 0pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#160;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="font-size: 10pt;">
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title of each class</div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: bottom; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr style="font-size: 10pt;">
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: top; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:Security12bTitle" id="ixv-363">Common Stock</ix:nonNumeric></div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: top; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" name="dei:TradingSymbol" id="ixv-364">ZVRA</ix:nonNumeric></div>
			</td>
			<td style="border: thin solid rgb(0, 0, 0); width: 33.3%; vertical-align: middle; font-size: 10pt;">
			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The <ix:nonNumeric contextRef="d20248K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-365">Nasdaq</ix:nonNumeric> Stock Market LLC</div>

			<div style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Nasdaq Global Select Market)</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;<span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Emerging growth company&#160; &#160;<ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-366">&#9744;</ix:nonNumeric></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a<span style="font-family: Times New Roman, Times, serif; font-size: 10pt;">) of the Exchange Act.&#160; &#160;&#9744;</span></div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;"><b>Item 7.01</b>&#160;<b> </b>&#160;<b> </b>&#160;<b> </b>&#160;<b> </b>&#160;<b> Regulation FD Disclosure.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On September 20, 2024, Zevra Therapeutics, Inc., a rare disease therapeutics company&#160;(the Company), issued a press release announcing&#160;that the U.S. Food and Drug Administration (FDA) has approved MIPLYFFA&#8482; (MY-PLY-FAH) (arimoclomol) capsules as an orally delivered treatment for Niemann-Pick disease type C (NPC). The first NPC drug approved by the FDA, MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older.&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;"><b>Item 8.01.</b>&#160; &#160; &#160; &#160; &#160;&#160;<b>Other Events.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">As noted in Item 7.01 above, on September&#160;20, 2024, the Company announced that the&#160;FDA approved MIPLYFFA&#160;capsules as an orally delivered treatment for NPC. In addition, the Company announced that it has received a rare pediatric disease priority review voucher in conjunction with the approval.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -2pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -2pt;"><b>Caution Concerning Forward-Looking Statements</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">This Current Report on Form 8-K&#160;may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra&#8217;s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, Zevra&#8217;s quarterly report for the three months ended June 30, 2024, and Zevra&#8217;s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this Current Report on Form 8-K.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Item 9.01.</b>&#160; &#160; &#160; &#160; &#160;&#160;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(d)&#160;Exhibits</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Exhibit No.</b></div>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 93%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Description</b></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">99.1</div>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_726150.htm" style="-sec-extract:exhibit;">Press Release dated September&#160;20, 2024.</a></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">104</div>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div class="PGNUM" style="width: 100%; text-align: center;">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="width: 100%; text-align: left;">&#160;</div>
</div>

<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</div>

<div style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>SIGNATURES</b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" id="TBL8" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="width: 45.4%; vertical-align: top;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td colspan="2" style="width: 49.6%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Zevra Therapeutics, Inc</b></span><span style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>.</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: middle;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">Date: September&#160;20, 2024</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">By:</div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">/s/ Timothy J. Sangiovanni</div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: middle;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&#160;</b></div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Timothy J. Sangiovanni, CPA</div>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&#160;</b></div>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Senior Vice President, Finance and&#160;Corporate Controller</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_726150.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_726150.htm</title>
	<!-- Generated by ThunderDome Portal - 9/20/2024 5:17:08 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><img alt="picture3.jpg" src="picture3.jpg"></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><font style="font-size:12pt;"><font style="font-family:'Calibri',Arial,sans-serif;"><b>Zevra Therapeutics</b>&#8217;<b> MIPLYFFA</b>&#8482;<b> (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C </b></font></font></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><i>MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative</i> <i>disease</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><i>MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adults and pediatric patients 2 years of age and older</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><i>Zevra receives rare pediatric disease priority review voucher in conjunction with approval</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><i>Company launches AmplifyAssist</i>&#8482;<i> patient support program</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><i>Conference call and webcast set for 8:00 a.m. EDT on Monday, Sept. 23, 2024</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>CELEBRATION, Fla. </b>&#8211;<b> Sept. 20, 2024</b> (GLOBE NEWSWIRE) &#8211;&nbsp;Zevra Therapeutics, Inc.&nbsp;(NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has approved MIPLYFFA&#8482; (MY-PLY-FAH) (arimoclomol) capsules as an orally delivered treatment for Niemann-Pick disease type C (NPC). The first NPC drug approved by the FDA, MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older. In addition, the Company announced that it has received a rare pediatric disease priority review voucher (PRV) in conjunction with the approval.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">&#8220;NPC is an ultra-rare, relentlessly progressive, degenerative, and fatal disease for which there were no FDA-approved treatment options until today,&#8221; said Neil F. McFarlane, President and Chief Executive Officer of Zevra Therapeutics, Inc. &#8220;The approval of MIPLYFFA is a monumental milestone for NPC patients and their family members in the U.S. We are immensely grateful for the unwavering support we have received over the years from the families and individuals impacted by NPC as well as the collaborative efforts of advocacy groups, researchers, and clinicians.&#8221;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">In the U.S., it is estimated that 900 people are living with NPC, of which approximately one-third have been diagnosed with this ultra-rare, relentlessly progressive, and fatal neurodegenerative disease.<sup style="vertical-align:top;line-height:120%;">i</sup> Both children and adults can be affected by NPC with varying clinical presentations. Characteristically, those living with NPC experience progressive physical and cognitive limitations, with key neurological impairments presenting in speech, cognition, swallowing, ambulation, and fine motor skills.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">&#8220;Until now, those living with NPC have had no FDA-approved treatment to combat this devastating disease,&#8221; said Laurie Turner, Family Services Manager, National Niemann-Pick Disease Foundation (NNPDF). &#8220;For more than 30 years, NNPDF and the community have been working to find treatments for NPC, and we are grateful for the diligence and commitment of the researchers, clinicians, families and Zevra for making this approval possible.&#8221;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">&#8220;The FDA approval of MIPLYFFA marks a significant moment for those living with NPC and the global NPC community,&#8221; <i>stated Dr. Elizabeth Berry-Kravis, Professor, Departments of Pediatrics, Neurological Sciences, Anatomy and Cell Biology, Director, RUSH Pediatric Neurosciences F.A.S.T. Center for Translational Research at Rush University Medical Center, </i>&#8220;Effective management of NPC requires multiple treatment options due to the complexity of the disease. Until today, there were no approved therapies in the U.S. for NPC. With this labeled indication, patients will now have more access to treatments to tackle this devastating disease.&#8221;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">The approval of MIPLYFFA for the treatment of NPC is based on the totality of the data in the New Drug Application (NDA), which included additional evidence supporting trial endpoints, FDA-preferred analyses, and additional confirmatory evidence, both clinical and nonclinical. The safety and effectiveness of MIPLYFFA was studied in a 12-month multicenter, randomized, double-blind, placebo-controlled trial in patients with NPC between two and 19 years of age. In this trial, 76% of patients in the MIPLYFFA group and 81% of those in the placebo group received miglustat as part of their routine care. The effectiveness of MIPLYFFA was evaluated using the rescored 4-domain NPC Clinical Severity Scale (R4DNPCCSS). Results from this trial demonstrated:</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">

		<tr style="font-family: Calibri, Arial, sans-serif; font-size: 11pt;">
			<td style="width: 18pt; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 18pt; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="vertical-align: top; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">MIPLYFFA, in combination with miglustat, halted disease progression through 12 months of treatment, as demonstrated by a decrease of 0.2 points from baseline on the R4DNPCCSS compared to 1.9 points of progression for patients treated with miglustat alone.</p>
			</td>
		</tr>

</table>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Additional confirmatory evidence included data from a 48-month open-label extension study which suggested improved outcomes when compared to a matched National Institutes of Health NPC natural history cohort.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">MIPLYFFA is administered orally, three times a day with or without food, with the exact dosage ranging from 47 mg to 124 mg dependent on body weight, by appropriate patients or caregivers with follow-up from a healthcare provider. Healthcare providers and patients/caregivers should refer to the Full and Instructions for Use for information on the proper administration of MIPLYFFA.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Zevra will immediately initiate its launch activities for MIPLYFFA, which is expected to be commercially available in the U.S. in eight to 12 weeks.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Launch of AmplifyAssist</b><b><sup style="vertical-align:top;line-height:120%;">TM</sup></b><b> </b>&#8212;<b><sup style="vertical-align:top;line-height:120%;"> </sup></b><b>Comprehensive Support for Patients </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Zevra is committed to assisting those whose lives are affected by NPC to overcome the barriers and challenges that may impact their treatment journey. The Company today launched AmplifyAssist, Zevra&#8217;s comprehensive patient support program. The mission of the program is to support the individual needs of eligible patients and those who care for them. Available resources include personalized insurance coverage education and support, copay and alternate funding identification assistance for eligible patients<sup style="vertical-align:top;line-height:120%;">, </sup>product needs, disease state information and therapy management counseling, and ongoing interactions to address barriers while facilitating timely prescription refills. Information about the program is available at MIPLYFFA.com or via telephone. The AmplifyAssist<sup style="vertical-align:top;line-height:120%;"> </sup>team can be reached toll-free at (888) 668-4198 from 8 a.m. CT to 6 p.m. CT Monday through Friday. Healthcare providers who want to submit prescriptions can visit MIPLYFFA.com to complete the prescription enrollment form that initiates the process for accessing the treatment.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Conference Call and Webcast Information </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Zevra Therapeutics, Inc. will host a conference call and audio webcast at 8 a.m. ET on Monday, September 23, 2024, to discuss FDA approval of MIPLYFFA. A link to the audio webcast will be accessible via the Investor Relations section of the Company&#8217;s website, https://investors.zevra.com/. To join the meeting by conference call, use the dial-in information below:</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">(800) 267-6316 (U.S.)</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">+1 (203) 518- 9783 (International)</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">Conference ID: ZVRA0923</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">An archive of the webcast will be available for ninety (90) days beginning at approximately 9 a.m. ET, on September 23, 2024, at https://investors.zevra.com/.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>About MIPLYFFA</b>&#8482;<b> (arimoclomol)</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. MIPLYFFA has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. MIPLYFFA was granted Breakthrough Therapy designation, Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation by the FDA for the treatment of NPC. MIPLYFFA was further granted Orphan Medicinal Product designation by the&nbsp;European Medicines Agency&nbsp;(EMA) for the treatment of NPC.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;"><b>INDICATIONS AND USAGE</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;"><b>IMPORTANT SAFETY INFORMATION</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;"><b>Hypersensitivity Reactions: </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1: two patients reported both urticaria and angioedema (6%) and one patient (3%) experienced urticaria alone within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, stop MIPLYFFA and treat promptly. Monitor the patient until signs and symptoms resolve.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;"><b>Embryofetal Toxicity: </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">MIPLYFFA may cause embryofetal harm when administered during pregnancy based on findings from animal reproduction studies. Advise pregnant females of the potential risk to the fetus and consider pregnancy planning and prevention for females of reproductive potential.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Increased Creatinine without Affecting Glomerular Function: </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">Across clinical trials of MIPLYFFA, mean increases in serum creatinine of 10% to 20% compared to baseline were reported. These increases occurred mostly in the first month of MIPLYFFA treatment and were not associated with changes in glomerular function.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function. Increases in creatinine reversed upon MIPLYFFA discontinuation.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>The most common adverse reactions</b> in Trial 1 (&#8805;15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1: increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients). Serious adverse reactions reported in MIPLYFFA-treated patients were hypersensitivity reactions including urticaria and angioedema.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1</b>&#8209;<b>800-FDA-1088 or </b><b>www.fda.gov/medwatch</b><b>.</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Drug Interaction(s): </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Arimoclomol is an inhibitor of the organic cationic transporter<br>
2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates. When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate<i>.</i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Use in Females and Males of Reproductive Potential:</b><i> </i></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">Based on animal findings, MIPLYFFA may impair fertility and may increase post-implantation loss and reduce maternal, placental, and fetal weights.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Renal Impairment: </b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR &#8805;15 mL/minute to &lt;50 mL/minute is lower than the recommended dosage (less frequent dosing) in patients with normal renal function.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">MIPLYFFA capsules for oral use are available in the following strengths: 47 mg, 62 mg, 93 mg, and 124 mg.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>About Niemann-Pick Disease Type C (NPC)</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify;">Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder characterized by an inability of the body to transport cholesterol and other lipids within the cell, leading to an accumulation of these substances in various cell types, including neurons. The disease is caused by mutations in the <i>NPC1</i> or <i>NPC2</i> genes, which are responsible for making the <i>NPC1</i> and <i>NPC2 </i>lysosomal proteins. Both children and adults can be affected by NPC with varying clinical presentations. Those living with NPC can lose independence due to physical and cognitive limitations, with key neurological impairments presenting in speech, cognition, swallowing, ambulation, and fine motor skills. Disease diagnosis can often take years, with disease progression being irreversible and often leading to early mortality.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>About Zevra Therapeutics, Inc.</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">Expanded access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy, as published on its website . Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Cautionary Note Concerning Forward-Looking Statements</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra&#8217;s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, Zevra&#8217;s quarterly report for the three months ended June 30, 2024, and Zevra&#8217;s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; text-align: justify; margin: 0pt;">_____________________________________________</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">

		<tr style="font-family: Calibri, Arial, sans-serif; font-size: 11pt;">
			<td style="width: 18pt; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 18pt; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">i.</p>
			</td>
			<td style="vertical-align: top; font-family: Calibri, Arial, sans-serif; font-size: 11pt;">
			<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">Burton et.al., Molecular Genetics and Metabolism Volume 134, Issues 1&#8211;2, September&#8211;October 2021, Pages 182-187</p>
			</td>
		</tr>

</table>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;"><b>Zevra Contact</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">Nichol Ochsner<br>
+1 (732) 754-2545<br>
nochsner@zevra.com</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;"><b>Russo Partners Contacts</b></p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">David Schull<br>
+1 (858) 717-2310</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">david.schull@russopartnersllc.com</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Calibri, Arial, sans-serif; font-size: 11pt; font-variant: normal; margin: 0pt;">Ignacio Guerrero-Ros, Ph.D.<br>
+1 (646) 942-5604<br>
ignacio.guerrero-ros@russopartnersllc.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zvra-20240920.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/20/2024 8:11:14 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:zvra="http://www.zvra.com/20240920" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.zvra.com/20240920">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20240920_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20240920_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20240920_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.zvra.com/20240920/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="zvra_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>zvra-20240920_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/20/2024 8:11:14 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.zvra.com/20240920/role/statement-document-and-entity-information" xlink:href="zvra-20240920.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.zvra.com/20240920/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>zvra-20240920_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/20/2024 8:11:14 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>zvra-20240920_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/20/2024 8:11:14 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.zvra.com/20240920/role/statement-document-and-entity-information" xlink:href="zvra-20240920.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.zvra.com/20240920/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>picture3.jpg
<TEXT>
begin 644 picture3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M(\D0\M$C"A/-C+O(BA@2 >7(_:2P>)G3MS>[J[::N^KTV'+<_5$?\&Y2E?\
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MC. 7(%?SD_LN_M;>'_V&?^"U'C'XF^*[#6-0\.Z'X]\7V]\FEQ++<Q+<7][
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M6'L?CK]H.]_X)2?\$DF\7_$&T6^UOX<Z)%I_V1+CSXKN]DN5M+./S<\0M)+
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M91F21I4S"!%@.Q8"OH;_ (*U:5)K7_!+_P#:%M[>%9KJ;X<:_%"IV@EFL)@
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<#&4;55BBBO4Q%2%&7)[.,M$[N]]=>C2_ 1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45260521202784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 20, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">Zevra Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Sep. 20,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-36913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">20-5894398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">1180 Celebration Boulevard, Suite 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Celebration<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">34747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">939-3416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZVRA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001434647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3>L=0%-\!W7$^S&^:JE,E'P76=08W1;1QR>*K2XA'FGXW[--I#8\8:\B/[J
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M@NV ]Q=2FOV)W>56/U(,_P-02P,$%     @ @8$T69^@&_"Q @  X@P   T
M  !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV
M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S
MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.
MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#
M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6
M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H
MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_
MC!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK
M'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?
MK7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*
MLN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-
MM[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]
MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7
MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L
M"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9G
MD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ @8$T69>*
MNQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q
M%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(
MMB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!
M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B
M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M@8$T6?C\Z+3N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ @8$T69E<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "!@319MVZI
M0DD$  "P$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ @8$T69^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zvra20240920_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zvra.com/20240920/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>zvra-20240920.xsd</File>
    <File>zvra-20240920_def.xml</File>
    <File>zvra-20240920_lab.xml</File>
    <File>zvra-20240920_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="zvra20240920_8k.htm">zvra20240920_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zvra20240920_8k.htm": {
   "nsprefix": "zvra",
   "nsuri": "http://www.zvra.com/20240920",
   "dts": {
    "schema": {
     "local": [
      "zvra-20240920.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "zvra-20240920_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "zvra-20240920_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zvra-20240920_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zvra20240920_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.zvra.com/20240920/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zvra20240920_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zvra20240920_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.zvra.com/20240920/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-24-029747-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-029747-xbrl.zip
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M/[L.CF'SI'+]R</'QXTYV?0!K#2'Q8=1!_$>%:SCB\P97&RK!8;.=+,-G$G
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M60M]HK3O,8E7TG4>9]YR_U""&^:@6)"83,0\3O@TB?9RD_F^5XV9MZ(6=D9
M#7N/@I[SJ:FTMP_#X$;8(SB5'LB+2ON:*VNQB@ZI;J0]"MRGVV$X27K0G[=6
M]A)("Y/4%*'.XMD4:UAZ;]6J\O"7L<4EK&658_8J_6\E<[56D&&9YU" ]CW
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M KM MNN_9D1+2J?%+Y .RFEBI>P=AJ75L,A=/7J37Z1B+X.!=M3?'US1!F9
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MOX7EZK)?T"+%BP1Q#1>\248HK<^.%S9.XE%LW:P_(MGO4\4G_P%02P,$%
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M$FSXUZ=3B?I1_]F+=_X%4$L#!!0    ( (&!-%E=,X#3D14  ,:2   3
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MYU&H;,S")'*F9_KMQ@1?;TSL\'TICZZT_N81R$.WCA)N\VW?^M;>$6[QK#X
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MGSA'_P=02P$"% ,4    " "!@319D@A79CX<  "/A   #0
M@ $     97A?-S(V,34P+FAT;5!+ 0(4 Q0    ( (&!-%G_@Y0#: ,  &X-
M   1              "  6D<  !Z=G)A+3(P,C0P.3(P+GAS9%!+ 0(4 Q0
M   ( (&!-%EA_.KEV00  .4L   5              "  0 @  !Z=G)A+3(P
M,C0P.3(P7V1E9BYX;6Q02P$"% ,4    " "!@319.0PNE_@%  !#/   %0
M            @ $,)0  >G9R82TR,#(T,#DR,%]L86(N>&UL4$L! A0#%
M  @ @8$T63Q+0]AU!   ?2T  !4              ( !-RL  'IV<F$M,C R
M-# Y,C!?<')E+GAM;%!+ 0(4 Q0    ( (&!-%E=,X#3D14  ,:2   3
M          "  =\O  !Z=G)A,C R-# Y,C!?.&LN:'1M4$L%!@     &  8
*A $  *%%      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>zvra20240920_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zvra-20240920.xsd" xlink:type="simple"/>
    <context id="d20248K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434647</identifier>
        </entity>
        <period>
            <startDate>2024-09-20</startDate>
            <endDate>2024-09-20</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20248K" id="ixv-348">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20248K" id="ixv-349">0001434647</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20248K" id="ixv-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20248K" id="ixv-37">2024-09-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20248K" id="ixv-43">Zevra Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20248K" id="ixv-56">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20248K" id="ixv-60">001-36913</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20248K" id="ixv-64">20-5894398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20248K" id="ixv-88">1180 Celebration Boulevard, Suite 103</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20248K" id="ixv-98">Celebration</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20248K" id="ixv-104">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20248K" id="ixv-113">34747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20248K" id="ixv-130">321</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20248K" id="ixv-132">939-3416</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20248K" id="ixv-359">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20248K" id="ixv-360">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20248K" id="ixv-361">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20248K" id="ixv-362">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20248K" id="ixv-363">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20248K" id="ixv-364">ZVRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20248K" id="ixv-365">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20248K" id="ixv-366">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
